To notice, STAT3 inhibitors on tumor cells, used in combinatorial therapy with immunogenic chemotherapeutics such as anthracyclines, improve the outcome of immunogenic chemotherapy by stimulating the type-1 interferon production by cancer cells [36]. This evidence concerns the gene STAT3 and cancer.